N末端-前B型钠尿肽检测在诊断ACS中的临床应用

摘要

Objective To assess the value of N-terminal pro-B-type natriuretic peptide measined by point of care testing( FOCT) in acute coronary syndrome (ACS) patients on admission. Methods Blood levels of NT-pro-BNP of 95 ACS patients were tested by the Canadian FOCT response biomedical RAMP NT-proBNP assay. The relationship between the testing results and heart function, left ventricular ejection function (LVEF) , severity of coronary lesions was analysed. RdSUltS The blood NT-proBNP level in patients with ACS was significantly higher in AMI group than that in UAP group (P <0.05), NT-proBNP was positive correlation with heart function and was negative correlation with LVEF. The level of NT-proBNP measured were significantly higher in patients who had complex lesions compared with those who had simple lesions(P <0. 05). Conclusion There exists significant difference in plasma NT-proBNP levels among the patients with different kind of coronary heart diseases. The level of NT-proBNP meaiBured in ACS patients on admission is a useful criteria on the judgement of the severity of the patient, and it gives us additional information on clinical management.%目的 探讨急性冠脉综合征(ACS)患者,入院床旁检测(POCT)N末端B型钠尿肽原(NT-proBNP)的临床应用价值.方法 应用加拿大Response Biomedical公司RAMP(r)(锐普)荧光干式定量分析仪,检测了95例ACS 患者血清NT-proBNP的水平,分析其与临床心功能分级、左室射血分数(LVEF) 以及冠脉病变严重程度之间的关系.结果 ACS各组间血浆NT-proBNP含量比较差异有显著性,AMI组均显著高于UAP组;NT-proBNP含量与心功能分级呈正相关,与LVEF呈负相关,与冠脉病变程度呈正相关.结论 不同类型冠心病(CHD)患者血清NT-proBNP浓度存在差异,测定NT-proBNP水平有助于ACS患者疾病严重程度的判断,为临床诊疗提供依据.